Clinical Trials

Extranodal Extension, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05805072 2023-05-06

Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients

Phase NA Unknown

Leukemia, Myeloid, Acute

NCT02172872 2023-02-15

"InDACtion" vs "3+7" Induction in AML

606 enrolled

Leukemia, Myeloid, Acute

NCT03855371 2022-11-04

PANDA-T0

Phase 1 Unknown

5 enrolled

Leukemia, Myeloid, Acute

NCT05426798 2022-06-22

Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes

Phase 1 Unknown

73 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT05382390 2022-05-19

Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial

130 enrolled

Leukemia, Myeloid, Acute

NCT05362942 2022-05-05

Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia

52 enrolled

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05320640 2022-04-11

Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors

Lymphoma, Non-Hodgkin

NCT05265962 2022-03-04

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

85 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05258799 2022-02-28

Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study

Phase NA Unknown

130 enrolled

Leukemia, Myeloid, Acute

NCT05137886 2021-12-17

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

47 enrolled

Hodgkin Disease, Recurrence

NCT04752527 2021-11-15

Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features

42 enrolled

Leukemia, Myeloid, Acute

NCT03257241 2021-10-01

PALG-AML1/2016

582 enrolled

Leukemia, Myeloid, Acute

NCT03467178 2021-09-05

MITO29

119 enrolled

Recurrence

NCT03080766 2021-04-28

The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype

Leukemia, Myeloid, Acute

NCT03530085 2020-12-22

Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT

60 enrolled

Leukemia, Myeloid, Acute

NCT04553393 2020-12-04

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

80 enrolled

Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden

NCT04025593 2020-11-19

Biomarker Guided Treatment in DLBCL

128 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04582604 2020-10-20

Ruxolitinib and Decitabine for High Risk Hematological Malignancies

60 enrolled

Peripheral Blood Stem Cell Transplantation

NCT04541277 2020-09-09

Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy

55 enrolled

Leukemia, Myeloid, Acute

NCT04514081 2020-08-18

The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

200 enrolled

Hodgkin Disease

NCT04233294 2020-08-14

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

Hodgkin Disease

NCT04510610 2020-08-12

Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Hodgkin Disease

NCT04279379 2020-05-07

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Lymphoma, Extranodal NK-T-Cell

NCT03417427 2020-04-27

A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

Pathologic Complete Response, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT04353479 2020-04-20

Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia

29 enrolled

Leukemia, Myeloid, Acute

NCT04337606 2020-04-07

Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor

Lymphoma, Non-Hodgkin

NCT02951728 2020-03-11

DR-CHOP

58 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04292769 2020-03-03

Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors

200 enrolled

Tumor-Agnostic

Neoplasms

NCT02272478 2020-01-23

AML18

1,600 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04168138 2019-11-19

D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

Phase NA Unknown

Leukemia, Myeloid, Acute

NCT04123392 2019-10-10

Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT

196 enrolled

Other neoplasm

TP53

NCT04098653 2019-09-23

Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT

196 enrolled

Other neoplasm

Allogeneic Hematopoietic Stem Cell Transplantation

NCT04087967 2019-09-12

Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients

162 enrolled

Leukemia, Myeloid, Acute

NCT04083911 2019-09-10

Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60

50 enrolled

Phase EARLY_PHASE1 Unknown

Leukemia, Myeloid, Acute

NCT04076137 2019-09-03

Targeted T-cell Therapy in Solid Tumors

10 enrolled

Other solid neoplasm

Malignant Solid Tumor

NCT04049344 2019-08-08

Decitabine Combined With Oxaliplatin in Patients With Advanced Renal Cell Carcinoma

25 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT01211457 2019-07-16

Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

65 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT03799224 2019-05-29

Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia

55 enrolled

Leukemia

NCT03250962 2019-04-01

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

280 enrolled

Hodgkin Disease, Recurrence

NCT03771222 2018-12-13

Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies

LymphoidOther hematologic neoplasm

40 enrolled

Graft vs Host Disease, Recurrence

NCT03558412 2018-09-14

A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma

Phase 4 Unknown

40 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03579082 2018-09-14

A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma

Phase 4 Unknown

60 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03553537 2018-06-12

Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Lymphoma, T-Cell, Peripheral

NCT03282825 2018-01-23

Clinical Study of Decitabine and Paclitaxel Combination Therapy

Phase 1 Unknown

18 enrolled

Breast

Advanced Breast Cancer

NCT03381781 2018-01-04

Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations

Leukemia, Myeloid, Acute

NCT03356080 2017-11-29

DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess

50 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03256071 2017-08-21

Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT

90 enrolled

Leukemia, Myeloid, Acute

NCT03026842 2017-01-20

Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)

Phase 4 Unknown

180 enrolled